Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130487 | 1.00 | FPR2 (0.49) | FPR2MMEMAPTALDH1A1HPGD | |
| SCHEMBL859719 | 0.89 | ALDH1A1 (0.52) | MMEMAPTALDH1A1HPGDKMT2A | |
| SCHEMBL29432860 | 0.89 | ALDH1A1 (0.52) | MMEMAPTALDH1A1HPGDKMT2A | |
| SCHEMBL4668778 | 0.88 | ALDH1A1 (0.48) | MMEMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL7572763 | 0.86 | HDAC8 (0.49) | MAPTALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL18738256 | 0.86 | HDAC8 (0.49) | MAPTALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL5955332 | 0.86 | HPGD (0.51) | FPR2MMEMAPTALDH1A1HPGD | |
| SCHEMBL27485422 | 0.86 | FPR2 (0.50) | FPR2MMEMAPTALDH1A1HPGD | |
| SCHEMBL4526295 | 0.85 | ALDH1A1 (0.50) | MMEMAPTALDH1A1HPGDKMT2A | |
| SCHEMBL8635820 | 0.85 | ALDH1A1 (0.50) | MMEMAPTALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | claimed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | claimed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | claimed |
| EP-3993818-A2 | CD38-BINDING AGENTS AND USES THEREOF | Kleo Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| CN-114401732-A | CD38 binding agents and uses thereof | 克莱奥药品有限公司 | 2022-04-26 | — | — | CN | claimed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250263440-A1 | CD38-BINDING AGENTS AND USES THEREOF | PEPTIDREAM INC. (JP) | 2025-08-21 | — | — | US | disclosed |
| CN-114269770-B | CD38 binding agents and uses thereof | 肽梦想株式会社 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
| CN-1151166-A | 3-Amino-2-oxo-1-piperidineacetic acid derivatives as enzyme inhibitors | CORVAS INT INC (US) | 1997-06-04 | — | — | CN | disclosed |
| EP-0494716-B1 | Enzyme-catalysed preparation of optically active carboxylic acids | DSM NV (NL) | 1996-08-28 | — | — | EP | disclosed |
| US-5248608-A | Enzyme catalyzed stereospecific hdyrolysis | DSM N.V. (NL) | 1993-09-28 | — | — | US | disclosed |
| EP-0494716-A2 | Enzyme-catalysed preparation of optically active carboxylic acids | DSM N.V. (NL) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263440-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, IGSF11, MCL1 | FPR2 3479/4885MME 311/4885MAPT 3840/4885 |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | FPR2 1858/4885MME 548/4885MAPT 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.